N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 3 , R 4 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
1 . (canceled)
2 . A compound having the structure:
and pharmaceutically acceptable salts thereof.
3 . A composition comprising a compound, or its pharmaceutically acceptable salt thereof, according to claim 2 and a pharmaceutically acceptable diluent or carrier.
4 . A method of treating cancer that over-expresses HER2 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound, or its pharmaceutically acceptable salt thereof, according to claim 2 .
5 . The method of claim 4 , wherein the cancer is breast cancer.
6 . The method of claim 4 , wherein an anti-tumor agent is administered in combination.
7 . The method of claim 6 , wherein the anti-tumor agent is an inhibitor of growth factor.
8 . The method of claim 7 , wherein the inhibitor of growth factor is trastuzumab.
9 . The method of claim 5 , wherein an anti-tumor agent is administered in combination.
10 . The method of claim 9 , wherein the anti-tumor agent is an inhibitor of growth factor.
11 . The method of claim 10 , wherein the inhibitor of growth factor is trastuzumab.